home | contact | pubmed search | Keyword Search:
ImmuneDisease.com logo Patients & FamiliesHealthcare ProfessionalsGAMMAGARD

Baxter IVIG Formulations

Baxter Support Services

Order Therapeutics

Important Safety Information

Prescribing Information

Sign Up Today

The Immune Disease eNewsletter gives you the latest updates.

Brought to you by Baxter

Baxter IVIG Formulations

GAMMAGARD offers 3 IVIG formulations, all with best-in-class support from Baxter.

GAMMAGARD LIQUID [Immune globulin Intravenous (Human)] 10%

  • No added sugars, sodium, or preservatives, plus latex-free packaging1
  • Dedicated 3-step process for viral inactivation/removal1
  • 9-month storage at room temperature (25°C [77°F]) within 24 months of manufacture1

Learn more about GAMMAGARD LIQUID

GAMMAGARD S/D [Immune globulin Intravenous (Human)]

  • Solvent/detergent treated2
  • 24-month shelf life2

Learn more about GAMMAGARD S/D

GAMMAGARD S/D [Immune Globulin Intravenous (Human)], IgA less than 1 µg/mL in a 5% solution

  • For patients who require low IgA therapy

Learn more about GAMMAGARD S/D with IgA less than 1 µg/mL in a 5% solution

 

gammagard comparison chart

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see the Important Safety Information and Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

GAMMAGARD S/D and GAMMAGARD S/D, IgA less than 1 µg/mL in a 5% solution are indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. GAMMAGARD S/D must not be used in patients with selective IgA deficiency (IgA < 0.05 g/L) where the IgA deficiency is the only abnormality of concern.

Please see the Important Safety Information and Full Prescribing Information for GAMMAGARD S/D [Immune Globulin Intravenous (Human)]

Please see the Important Safety Information and Full Prescribing Information for GAMMAGARD S/D [Immune Globulin Intravenous (Human)], IgA less than 1 µg/mL in a 5% solution.

1. GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% package insert. Deerfield, IL. Baxter International Inc.; April 2005.
2. GAMMAGARD S/D [Immune Globulin Intravenous (Human)] package insert. Deerfield, IL. Baxter International Inc.; January 2005.

This site is intended for use only by residents of the United States. Copyright 2005 Baxter Healthcare Corporation. All Rights Reserved